158 related articles for article (PubMed ID: 36553503)
1. Trajectories of Kidney Function in Patients with ATTRv Treated with Gene Silencers.
Luigetti M; Guglielmino V; Romano A; Sciarrone MA; Vitali F; D'Ambrosio V; Ferraro PM
Genes (Basel); 2022 Nov; 13(12):. PubMed ID: 36553503
[TBL] [Abstract][Full Text] [Related]
2. Natural course and determinants of short-term kidney function decline in hereditary transthyretin amyloidosis: a French observational study.
Dang J; Segaux L; Moktefi A; Stehlé T; Kharoubi M; El Karoui K; Rémy P; Grimbert P; Plante-Bordeneuve V; Guendouz S; Galat A; Mallet S; Oghina S; Chadha GDS; Zaroui A; Fanen P; Canoui-Poitrine F; Damy T; Audard V
Amyloid; 2023 Mar; 30(1):38-48. PubMed ID: 35848215
[TBL] [Abstract][Full Text] [Related]
3. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.
Carroll A; Dyck PJ; de Carvalho M; Kennerson M; Reilly MM; Kiernan MC; Vucic S
J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):668-678. PubMed ID: 35256455
[TBL] [Abstract][Full Text] [Related]
4. Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy.
Luigetti M; Antonini G; Di Paolantonio A; Gentile L; Grandis M; Leonardi L; Lozza A; Manganelli F; Mazzeo A; Mussinelli R; My F; Obici L; Maria Pennisi E; Romozzi M; Russo M; Sabatelli M; Salvalaggio A; Tagliapietra M; Tozza S
Eur J Neurol; 2022 Jul; 29(7):2148-2155. PubMed ID: 35289020
[TBL] [Abstract][Full Text] [Related]
5. Hereditary Transthyretin Amyloidosis and the Impact of Classic and New Treatments on Kidney Function: A Review.
Meléndrez-Balcázar E; Aranda-Vela K; Cervantes-Hernández A; López-Cureño S
Am J Kidney Dis; 2024 Mar; ():. PubMed ID: 38484868
[TBL] [Abstract][Full Text] [Related]
6. [Gene therapy options for hereditary transthyretin-related amyloidosis].
Schilling M
Nervenarzt; 2022 Jun; 93(6):557-565. PubMed ID: 35419654
[TBL] [Abstract][Full Text] [Related]
7. Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study.
Qarni TN; Jones FJS; Drachman B; Khella S; Pieretti J; Bustamante NS; Karam C
Orphanet J Rare Dis; 2024 May; 19(1):191. PubMed ID: 38720335
[TBL] [Abstract][Full Text] [Related]
8. Pathological spectrum of hereditary transthyretin renal amyloidosis and clinicopathologic correlation: a French observational study.
Dang J; Ferlicot S; Misrahi M; Mussini C; Kounis I; Rémy P; Samuel D; Planté-Bordeneuve V; Adams D; Funalot B; Snanoudj R; Damy T; Moktefi A; Audard V; Zaidan M
Nephrol Dial Transplant; 2023 Aug; 38(9):2019-2030. PubMed ID: 36646436
[TBL] [Abstract][Full Text] [Related]
9. Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression.
Adams D; Algalarrondo V; Polydefkis M; Sarswat N; Slama MS; Nativi-Nicolau J
Orphanet J Rare Dis; 2021 Oct; 16(1):411. PubMed ID: 34602081
[TBL] [Abstract][Full Text] [Related]
10. Renal Involvement in Hereditary Transthyretin Amyloidosis: An Italian Single-Centre Experience.
Ferraro PM; D'Ambrosio V; Di Paolantonio A; Guglielmino V; Calabresi P; Sabatelli M; Luigetti M
Brain Sci; 2021 Jul; 11(8):. PubMed ID: 34439599
[TBL] [Abstract][Full Text] [Related]
11. An Exploratory Study of Cognitive Involvement in Hereditary Transthyretin Amyloidosis.
Durmuş H; Çakar A; Demirci H; Alaylioglu M; Gezen-Ak D; Dursun E; Gülşen Parman Y
Acta Neurol Scand; 2021 Dec; 144(6):640-646. PubMed ID: 34322872
[TBL] [Abstract][Full Text] [Related]
12. Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis.
Ticau S; Sridharan GV; Tsour S; Cantley WL; Chan A; Gilbert JA; Erbe D; Aldinc E; Reilly MM; Adams D; Polydefkis M; Fitzgerald K; Vaishnaw A; Nioi P
Neurology; 2021 Jan; 96(3):e412-e422. PubMed ID: 33087494
[TBL] [Abstract][Full Text] [Related]
13. A Metabolic Signature of Hereditary Transthyretin Amyloidosis: A Pilot Study.
Luigetti M; Guglielmino V; Romano A; Sciarrone MA; Vitali F; Sabino A; Gervasoni J; Primiano A; Santucci L; Moroni R; Primiano G
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555770
[TBL] [Abstract][Full Text] [Related]
14. Italian Real-Life Experience of Patients with Hereditary Transthyretin Amyloidosis Treated with Patisiran.
Di Stefano V; Fava A; Gentile L; Guaraldi P; Leonardi L; Poli L; Tagliapietra M; Vastola M; Fanara S; Ferrero B; Giorgi M; Perfetto F; Russo M; Russo D
Pharmgenomics Pers Med; 2022; 15():499-514. PubMed ID: 35592550
[TBL] [Abstract][Full Text] [Related]
15. Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus.
Grandis M; Obici L; Luigetti M; Briani C; Benedicenti F; Bisogni G; Canepa M; Cappelli F; Danesino C; Fabrizi GM; Fenu S; Ferrandes G; Gemelli C; Manganelli F; Mazzeo A; Melchiorri L; Perfetto F; Pradotto LG; Rimessi P; Tini G; Tozza S; Trevisan L; Pareyson D; Mandich P
Orphanet J Rare Dis; 2020 Dec; 15(1):348. PubMed ID: 33317601
[TBL] [Abstract][Full Text] [Related]
16. Identification and management of gastrointestinal manifestations of hereditary transthyretin amyloidosis: Recommendations from an Italian group of experts.
Cappello M; Barbara G; Bellini M; Consalvo D; Di Sabatino A; Marasco G; Principi M; Savarino EV; Tortora A; Obici L
Dig Liver Dis; 2024 Jun; 56(6):1014-1020. PubMed ID: 38105149
[TBL] [Abstract][Full Text] [Related]
17. Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience.
Ungerer MN; Hund E; Purrucker JC; Huber L; Kimmich C; Aus dem Siepen F; Hein S; Kristen AV; Hinderhofer K; Kollmer J; Schönland S; Hegenbart U; Weiler M
Amyloid; 2021 Jun; 28(2):91-99. PubMed ID: 33283548
[TBL] [Abstract][Full Text] [Related]
18. Variant Transthyretin Amyloidosis (ATTRv) in Hungary: First Data on Epidemiology and Clinical Features.
Pozsonyi Z; Peskó G; Takács H; Csuka D; Nagy V; Szilágyi Á; Hategan L; Muk B; Csányi B; Nyolczas N; Dézsi L; Molnár JM; Csillik A; Révész K; Iványi B; Szabó F; Birtalan K; Masszi T; Arányi Z; Sepp R
Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440326
[TBL] [Abstract][Full Text] [Related]
19. Chance or challenge, spoilt for choice? New recommendations on diagnostic and therapeutic considerations in hereditary transthyretin amyloidosis with polyneuropathy: the German/Austrian position and review of the literature.
Dohrn MF; Auer-Grumbach M; Baron R; Birklein F; Escolano-Lozano F; Geber C; Grether N; Hagenacker T; Hund E; Sachau J; Schilling M; Schmidt J; Schulte-Mattler W; Sommer C; Weiler M; Wunderlich G; Hahn K
J Neurol; 2021 Oct; 268(10):3610-3625. PubMed ID: 32500375
[TBL] [Abstract][Full Text] [Related]
20. Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS.
Caponetti AG; Rapezzi C; Gagliardi C; Milandri A; Dispenzieri A; Kristen AV; Wixner J; Maurer MS; Garcia-Pavia P; Tournev I; Planté-Bordeneuve V; Chapman D; Amass L;
JACC Heart Fail; 2021 Oct; 9(10):736-746. PubMed ID: 34391735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
